Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774771 | 0.91 | AGTR1 (0.54) | AGTR1PPARG | |
| SCHEMBL13070234 | 0.88 | AGTR1 (0.54) | AGTR1HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL2774113 | 0.88 | AGTR1 (0.48) | AGTR1HDAC1HDAC8HDAC6PPARG | |
| SCHEMBL2776246 | 0.85 | AGTR1 (0.57) | AGTR1 | |
| SCHEMBL2774054 | 0.83 | HDAC1 (0.60) | AGTR1HDAC1HDAC8HDAC6PPARG | |
| SCHEMBL2775724 | 0.83 | AGTR1 (0.77) | AGTR1 | |
| SCHEMBL2774436 | 0.81 | AGTR1 (0.62) | AGTR1 | |
| SCHEMBL2775718 | 0.81 | AGTR1 (0.51) | AGTR1PPARG | |
| SCHEMBL13475108 | 0.80 | AGTR1 (0.49) | AGTR1HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL2773447 | 0.79 | AGTR1 (0.49) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501750-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501750-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501750-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| EP-2253630-A1 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2151440-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151440-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PCSK9, APOB, REN | AGTR1 99/4885HDAC1 103/4885HDAC8 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.